Kezar Life Sciences (NASDAQ:KZR) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research downgraded shares of Kezar Life Sciences (NASDAQ:KZR) from a buy rating to a hold rating in a research note released on Wednesday, Zacks.com reports.

According to Zacks, “Kezar Life Sciences, Inc. is a bio-technology company. It discovers and develops molecule therapeutics and medicines such as protein homeostasis for autoimmune disorders. The company’s product pipeline consists of KZR-616 which is in clinical stage. Kezar Life Sciences, Inc. is headquartered in South San Francisco, California. “

Several other equities research analysts have also commented on the stock. Cowen reaffirmed a buy rating on shares of Kezar Life Sciences in a report on Thursday, August 8th. HC Wainwright started coverage on shares of Kezar Life Sciences in a report on Monday, July 29th. They issued a buy rating and a $15.00 price target on the stock. Finally, ValuEngine raised shares of Kezar Life Sciences from a hold rating to a buy rating in a report on Thursday, August 1st. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $9.25.

NASDAQ:KZR traded down $0.01 during mid-day trading on Wednesday, hitting $3.10. The company’s stock had a trading volume of 551 shares, compared to its average volume of 78,694. Kezar Life Sciences has a 1 year low of $2.82 and a 1 year high of $36.33. The company has a debt-to-equity ratio of 0.06, a current ratio of 20.32 and a quick ratio of 20.32. The stock has a market cap of $59.71 million, a price-to-earnings ratio of -1.37 and a beta of 0.86. The business’s fifty day moving average is $3.50 and its two-hundred day moving average is $10.22.

Kezar Life Sciences (NASDAQ:KZR) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.02. Analysts anticipate that Kezar Life Sciences will post -1.96 EPS for the current fiscal year.

Hedge funds have recently bought and sold shares of the company. Metropolitan Life Insurance Co NY purchased a new stake in shares of Kezar Life Sciences during the 1st quarter worth about $89,000. MetLife Investment Advisors LLC purchased a new stake in shares of Kezar Life Sciences during the 1st quarter worth $123,000. Rhumbline Advisers purchased a new stake in shares of Kezar Life Sciences during the 1st quarter worth $245,000. Acadian Asset Management LLC purchased a new stake in shares of Kezar Life Sciences during the 2nd quarter worth $107,000. Finally, A.R.T. Advisors LLC purchased a new stake in shares of Kezar Life Sciences during the 2nd quarter worth $112,000. 52.27% of the stock is currently owned by institutional investors and hedge funds.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis.

Further Reading: How to invest in a bear market

Get a free copy of the Zacks research report on Kezar Life Sciences (KZR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.